Multiple myeloma is treated by all, EXCEPT:

Relapsed myeloma can be treated with novel agents including lenalidomide and/or boezomib. Thalidomide, if not used as initial therapy, can achieve responses in refractory cases. High-dose melphalan and stem cell transplant, if not used earlier, also have activity in patients with refractory disease. Ref: Harrison's principle of internal medicine 17th edition, chapter 106.